{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T11:27:24Z","timestamp":1769340444362,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T00:00:00Z","timestamp":1417132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2415-14-151","type":"journal-article","created":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T19:37:31Z","timestamp":1417203451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Late-day intraocular pressure\u2013lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial"],"prefix":"10.1186","volume":"14","author":[{"given":"Harvey B","family":"DuBiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas A","family":"Hubatsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,28]]},"reference":[{"key":"529_CR1","volume-title":"Preferred Practice Pattern\u00ae Guidelines. Primary Open-Angle Glaucoma","author":"American Academy of Ophthalmology Glaucoma Panel","year":"2010","unstructured":"American Academy of Ophthalmology Glaucoma Panel: Preferred Practice Pattern\u00ae Guidelines. Primary Open-Angle Glaucoma. 2010, San Francisco, CA: American Academy of Ophthalmology"},{"issue":"6","key":"529_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002, 120 (6): 701-713. 10.1001\/archopht.120.6.701.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"529_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The Advanced Glaucoma Intervention Study (AGIS) Investigators","year":"2000","unstructured":"The Advanced Glaucoma Intervention Study (AGIS) Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000, 130 (4): 429-440.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"529_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998, 126 (4): 487-497.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"529_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00061198-200306000-00009","volume":"12","author":"E Hughes","year":"2003","unstructured":"Hughes E, Spry P, Diamond J: 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003, 12 (3): 232-236. 10.1097\/00061198-200306000-00009.","journal-title":"J Glaucoma"},{"issue":"5","key":"529_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/IJG.0b013e31815c5f3f","volume":"17","author":"CA McCarty","year":"2008","unstructured":"McCarty CA, Mukesh BN, Kitchner TE, Hubbard WC, Wilke RA, Burmester JK, Patchett RB: Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project. J Glaucoma. 2008, 17 (5): 372-377. 10.1097\/IJG.0b013e31815c5f3f.","journal-title":"J Glaucoma"},{"issue":"7432","key":"529_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/bmj.328.7432.156","volume":"328","author":"PT Khaw","year":"2004","unstructured":"Khaw PT, Shah P, Elkington AR: Glaucoma\u20132: treatment. BMJ. 2004, 328 (7432): 156-158. 10.1136\/bmj.328.7432.156.","journal-title":"BMJ"},{"key":"529_CR8","first-page":"519","volume":"23","author":"CB Camras","year":"1995","unstructured":"Camras CB: Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res. 1995, 23: 519-525.","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"issue":"2","key":"529_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/IJG.0b013e31802fc6d3","volume":"16","author":"CB Toris","year":"2007","unstructured":"Toris CB, Zhan G, Fan S, Dickerson JE, Landry TA, Bergamini MV, Camras CB: Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma. 2007, 16 (2): 189-195. 10.1097\/IJG.0b013e31802fc6d3.","journal-title":"J Glaucoma"},{"issue":"7","key":"529_CR10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R van der Valk","year":"2005","unstructured":"van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH: Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005, 112 (7): 1177-1185. 10.1016\/j.ophtha.2005.01.042.","journal-title":"Ophthalmology"},{"issue":"10","key":"529_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1185\/03007995.2011.613923","volume":"27","author":"F Aptel","year":"2011","unstructured":"Aptel F, Denis P: Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011, 27 (10): 1949-1958. 10.1185\/03007995.2011.613923.","journal-title":"Curr Med Res Opin"},{"issue":"suppl 1","key":"529_CR12","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","volume":"53","author":"A Alm","year":"2008","unstructured":"Alm A, Grierson I, Shields MB: Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008, 53 (suppl 1): S93-S105.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"529_CR13","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/eye.2012.195","volume":"26","author":"K Inoue","year":"2012","unstructured":"Inoue K, Shiokawa M, Higa R, Sugahara M, Soga T, Wakakura M, Tomita G: Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond). 2012, 26 (11): 1465-1472. 10.1038\/eye.2012.195.","journal-title":"Eye (Lond)"},{"issue":"2","key":"529_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1527-3466.2004.tb00134.x","volume":"22","author":"DF Woodward","year":"2004","unstructured":"Woodward DF, Phelps RL, Krauss AH, Weber A, Short B, Chen J, Liang Y, Wheeler LA: Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev. 2004, 22 (2): 103-120.","journal-title":"Cardiovasc Drug Rev"},{"issue":"10","key":"529_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","volume":"120","author":"EJ Higginbotham","year":"2002","unstructured":"Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, Whitcup SM, Bimatoprost Study Group: One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002, 120 (10): 1286-1293. 10.1001\/archopht.120.10.1286.","journal-title":"Arch Ophthalmol"},{"issue":"suppl 1","key":"529_CR16","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.survophthal.2003.12.019","volume":"49","author":"JS Cohen","year":"2004","unstructured":"Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM: Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004, 49 (suppl 1): S45-S52.","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"529_CR17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/bjo.2007.128454","volume":"92","author":"RD Williams","year":"2008","unstructured":"Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL, Bimatoprost Study G: Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol. 2008, 92 (10): 1387-1392. 10.1136\/bjo.2007.128454.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"529_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","volume":"149","author":"LJ Katz","year":"2010","unstructured":"Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM: Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010, 149 (4): 661-671. 10.1016\/j.ajo.2009.12.003. e661","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"529_CR19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1185\/03007995.2013.815160","volume":"29","author":"JH Campbell","year":"2013","unstructured":"Campbell JH, Schwartz G, Labounty B, Kowalski J, Patel VD: Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Curr Med Res Opin. 2013, 29 (9): 1201-1209. 10.1185\/03007995.2013.815160.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"529_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1442-9071.2006.01237.x","volume":"34","author":"N Li","year":"2006","unstructured":"Li N, Chen XM, Zhou Y, Wei ML, Yao X: Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol. 2006, 34 (8): 755-764. 10.1111\/j.1442-9071.2006.01237.x.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"12","key":"529_CR21","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1185\/030079905X74916","volume":"21","author":"G Hollo","year":"2005","unstructured":"Hollo G, Vargha P, Kothy P: Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication. Curr Med Res Opin. 2005, 21 (12): 1943-1948. 10.1185\/030079905X74916.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"529_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1185\/030079904125004448","volume":"20","author":"M Kaback","year":"2004","unstructured":"Kaback M, Geanon J, Katz G, Ripkin D, Przydryga J, START Study Group: Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin. 2004, 20 (9): 1341-1345. 10.1185\/030079904125004448.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"529_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/01.ijg.0000212274.50229.c6","volume":"16","author":"RA Lewis","year":"2007","unstructured":"Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, Hua SY, Sullivan EK, Montgomery DB, Wells DT, Bergamini MV, Travoprost BAC-free Study Group: Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007, 16 (1): 98-103. 10.1097\/01.ijg.0000212274.50229.c6.","journal-title":"J Glaucoma"},{"issue":"1","key":"529_CR24","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1111\/j.1755-3768.2012.02565.x","volume":"91","author":"M Aihara","year":"2013","unstructured":"Aihara M, Oshima H, Araie M, EXTraKT Study Group: Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface \u2013 a multicentre randomized single-masked study. Acta Ophthalmol. 2013, 91 (1): e7-e14. 10.1111\/j.1755-3768.2012.02565.x.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"529_CR25","first-page":"613","volume":"2","author":"JC Henry","year":"2008","unstructured":"Henry JC, Peace JH, Stewart JA, Stewart WC: Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008, 2 (3): 613-621.","journal-title":"Clin Ophthalmol"},{"key":"529_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2147\/OPTH.S13460","volume":"4","author":"MJ Miyashiro","year":"2010","unstructured":"Miyashiro MJ, Lo SC, Stewart JA, Stewart WC: Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients. Clin Ophthalmol. 2010, 4: 1355-1359.","journal-title":"Clin Ophthalmol"},{"key":"529_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2147\/OPTH.S30690","volume":"6","author":"HB Dubiner","year":"2012","unstructured":"Dubiner HB, Noecker R: Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clin Ophthalmol. 2012, 6: 525-531.","journal-title":"Clin Ophthalmol"},{"key":"529_CR28","first-page":"447","volume":"3","author":"O Eyawo","year":"2009","unstructured":"Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, Kelly S, Mills E: Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009, 3: 447-456.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"529_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C: Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002, 86 (4): 418-423. 10.1136\/bjo.86.4.418.","journal-title":"Br J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-14-151\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-14-151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T03:23:23Z","timestamp":1548213803000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-14-151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-14-151","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,28]]},"assertion":[{"value":"9 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"151"}}